John Byrd

John Byrd, MD


Make an Appointment


Overall Patient Satisfaction Rating

4.9 out of 5




I am a board certified hematologist and my area of focus is caring for patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Our multidisciplinary hematology group has extensive experience treating patients with novel therapeutics as part of clinical trials. Our goal is to eradicate the need for chemotherapy in the treatment of leukemia.

I hold the D. Warren Brown Chair of Leukemia Research, and serve as a professor of medicine, and medicinal chemistry and pharmacy for The Ohio State University. I‘m proud to have served in the military and did much of my training at Walter Reed Army Medical Center. I was named to the Castle Connolly list of “America's Top Doctors” from 2006-2019, as well as being rated in the top 10 percent of physicians in the nation for patient satisfaction in 2014, 2016 and 2017.

Additionally, I’m a member of the National Cancer Institute’s Leukemia Steering Committee, Chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology and member of the American Society of Clinical Investigation. I have published more than 400 papers related to clinical and laboratory investigation in AML and CLL.

The best cancer treatments have never been good enough for me. As long as people are still facing cancer, I’ll keep fighting. When researchers can focus on one type of cancer every day, like we do here at The James, we can discover amazing things. I’m just one of the many physicians looking for solutions to a multitude of cancers. And I won’t stop until we’re all living in a cancer-free world.

Education and Background


University of Arkansas College of Medicine

Little Rock, AR


Walter Reed Army Medical Center

Washington, DC


Medical Oncology

Walter Reed Army Medical Center

Washington, DC

Medical Oncology

Johns Hopkins Medical Center

Baltimore, MD

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Hematology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Hematology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 12/20/2018, Dr. Byrd has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

Leukemia and Lymphoma Society

Pharmacyclics, Inc.

Acerta Pharma

American Society of Hematology

Jazz Pharmaceuticals plc


Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 256 reviews)
4.9 out of 5
Kept you informed about your condition and treatment

4.9/ 5

Amount of time spent with you

4.8/ 5

Concern for your questions and issues

4.9/ 5

Skill and knowledge

4.9/ 5

Overall quality of care

4.9/ 5

Patient Comments (16 total comments)

Reviewed: 7/20/2019

Dr. Byrd is The Best!!

Reviewed: 6/16/2019


Reviewed: 5/10/2019

Not just the recognized expert in the field, but also a very nice guy. 4. Wow.

Reviewed: 5/4/2019

Dr Byrd is an excellent listener and explains well when I have questions. All the nurses are caring and competent.

Reviewed: 4/29/2019

Dr. Byrd is tremendous very caring, very informative about treatments and obviously a top-rated researcher.

Reviewed: 4/20/2019

Dr Byrd & his staff are top notch

Reviewed: 4/20/2019

Byrd is the best!!!!

Reviewed: 4/14/2019

Dr Byrd and PA M Lucas were very informative

Reviewed: 3/17/2019

How can you not like Dr. Byrd

Reviewed: 3/15/2019

Dr. Byrd is wonderful.


Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.

Moreno C, Delgado J, Byrd JC, Zvagelsky WL, Suzuki S, Hsu E, James DF, Montserrat E

Br J Haematol 185


Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC

Haematologica in press


Related Videos

Dr. John Byrd Discusses Beat AML Master Trial
Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type